← Leaderboards
Larry W. Markham
Vanderbilt University Medical Center
$463,617
Attributed
$2,021,527
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2024–25$2M$1.5M$1M$500K$0
'24
'25
Funding mix
By agency
NIH$2,021,527 · 2
By mechanism
R01$1,576,689 · 1
R61$444,838 · 1
Top collaborators
- Jonathan Harvey Soslow3 shared
- Craig J. Goergen2 shared
- Kan N Hor2 shared
- Guang Lin2 shared
- Christopher Fore Spurney1 shared
Most similar at Vanderbilt University Medical Center
Same institution · by research overlap
- Jonathan Harvey Soslow$5,426,669
- Alexander Tharrington Hawkins$2,097,749
- Wei-Qi Wei$9,737,275
- Simon Neil Vandekar$2,113,210
- Evan L Brittain$13,630,303
Others in their field
Other Rising Stars on “Future”
- Katherine M Thibault · Battelle Memorial Institute$134,148,552
- Mari Ostendorf · University Of Washington$51,931,230
- Jeffrey Leintz · National Opinion Research Center$40,628,545
- Eric M Benway · Woods Hole Oceanographic Institution$32,293,242
- Walt Lee$25,884,232
- Cyrus Wadia · Activate Global, Inc.$24,000,000
Research focus
FutureMagnetic ResonanceDuchenne CardiomyopathyFundingHeart FailureLeft Ventricular Ejection FractionCollectionCoronary FibrosisDuchenne Muscular DystrophyEvaluationBloodClinical TrialsImageInstitutionCardiacCardiac Magnetic Resonance ImagingCardiomyopathiesBiological MarkersCardiovascular SystemCaringDystrophinCause Of DeathCessation Of LifeMortality
Grant awards (3)
Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials$738,341
R01 · FY2025 · HL
CHERISH (duCHennE caRdiomyopathy mItigation Sglt2 inHibitor)$444,838
R61 · FY2025 · HL · contact PI
Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials$838,348
R01 · FY2024 · HL